title: ÐÐ±ÑÐ°ÑÐµÐ½Ð¸Ðµ Ñ Ð¶Ð¸Ð´ÐºÐ¸Ð¼Ð¸ ÑÐ°Ð´Ð¸Ð¾Ð°ÐºÑÐ¸Ð²Ð½ÑÐ¼Ð¸ Ð¾ÑÑ Ð¾Ð´Ð°Ð¼Ð¸ Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Sr-89, I-123
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Management of liquid radioactive waste after radionuclide therapy Sr-89, I-123
Creators: name: ÐÐµÐ»Ð¸ÑÐºÐ¸Ð½Ð°, ÐÑÐ¸ÑÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: ÑÐ´ÐµÑÐ½Ð°Ñ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½Ð°
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ°
ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ
nuclear medicine
radionuclide therapy
radionuclide diagnostics
radiopharmaceuticals

description: Ð¢ÐµÐ¼Ð° Ð²ÑÐ¿ÑÑÐºÐ½Ð¾Ð¹ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ: Â«ÐÐ±ÑÐ°ÑÐµÐ½Ð¸Ðµ Ñ Ð¶Ð¸Ð´ÐºÐ¸Ð¼Ð¸ ÑÐ°Ð´Ð¸Ð¾Ð°ÐºÑÐ¸Ð²Ð½ÑÐ¼Ð¸ Ð¾ÑÑÐ¾Ð´Ð°Ð¼Ð¸ Ð¿Ð¾ÑÐ»Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Sr-89, I-123Â».ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÐ°ÑÑÐ¼Ð¾ÑÑÐµÐ½Ð¸Ñ ÑÐ°Ð·Ð½ÑÑ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ¾Ð² Ð¾Ð±ÑÐ°ÑÐµÐ½Ð¸Ñ Ñ Ð¶Ð¸Ð´ÐºÐ¸Ð¼Ð¸ ÑÐ°Ð´Ð¸Ð¾Ð°ÐºÑÐ¸Ð²Ð½ÑÐ¼Ð¸ Ð¾ÑÑÐ¾Ð´Ð°Ð¼Ð¸ (ÐÐ Ð), Ð¾Ð±ÑÐ°Ð·ÑÑÑÐ¸ÑÑÑ Ð² Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸ÑÑ ÑÐ´ÐµÑÐ½Ð¾Ð¹ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½Ñ Ð¿ÑÐ¸ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ð¸ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ñ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð² (Ð Ð¤Ð) - 123I-ÐÐÐÐ, 89Sr-Ð´Ð¸ÑÐ»Ð¾ÑÐ¸Ð´.Ð¦ÐµÐ»Ñ ÑÐ°Ð±Ð¾ÑÑ Ð·Ð°ÐºÐ»ÑÑÐ°Ð»Ð°ÑÑ Ð² Ð¾ÑÐµÐ½ÐºÐµ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² Ð² Ð¾ÑÑÐ¾Ð´Ð°Ñ, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¾Ð±ÑÐ°Ð·ÑÑÑÑÑ Ð¿ÑÐ¸ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ð¸ 123I-ÐÐÐÐ Ð² ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐµ (Ð ÐÐ) Ð¸ 89Sr-Ð´Ð¸ÑÐ»Ð¾ÑÐ¸Ð´ Ð² ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ (Ð ÐÐ¢) Ð¸ Ð±ÐµÐ·Ð¾Ð¿Ð°ÑÐ½ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² Ð¾Ð±ÑÐ°ÑÐµÐ½Ð¸Ñ Ñ Ð´Ð°Ð½Ð½ÑÐ¼Ð¸ ÐÐ Ð. ÐÐ»Ñ Ð´Ð¾ÑÑÐ¸Ð¶ÐµÐ½Ð¸Ñ Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐµÐ»Ð¸ Ð±ÑÐ»Ð¸ Ð¿Ð¾ÑÑÐ°Ð²Ð»ÐµÐ½Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð·Ð°Ð´Ð°ÑÐ¸:ÐÐ·ÑÑÐ¸ÑÑ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÑ, ÑÐ²ÑÐ·Ð°Ð½Ð½ÑÑ Ñ ÑÐµÐºÐ¾Ð¼ÐµÐ½Ð´Ð°ÑÐ¸ÑÐ¼Ð¸ Ð¿Ð¾ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð´Ð°Ð½Ð½ÑÑ Ð Ð¤Ð, Ð¸Ñ Ð²ÑÐ²ÐµÐ´ÐµÐ½Ð¸ÐµÐ¼ Ð¸Ð· Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ð°;ÐÑÐ¾Ð²ÐµÑÑÐ¸ Ð¾ÑÐµÐ½ÐºÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² Ð² Ð¾ÑÑÐ¾Ð´Ð°Ñ;ÐÐ¿ÑÐµÐ´ÐµÐ»Ð¸ÑÑ Ð¾Ð±ÑÑÐ¼ ÐºÐ°Ð½Ð°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸ Ð² Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½ÑÐºÐ¾Ð¹ Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð°ÑÐ¸Ð¸ (ÐÐ) Ð´Ð¾ÑÑÐ°ÑÐ¾ÑÐ½ÑÐ¹ Ð´Ð»Ñ ÑÐ°Ð·Ð±Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ð¶Ð¸Ð´ÐºÐ¸Ñ Ð¾ÑÑÐ¾Ð´Ð¾Ð² Ð´Ð¾ Ð¿ÑÐµÐ´ÐµÐ»ÑÐ½Ð¾ Ð´Ð¾Ð¿ÑÑÑÐ¸Ð¼Ð¾Ð³Ð¾ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ñ.Ð Ð°ÑÑÑÐ¸ÑÐ°ÑÑ Ð¾Ð±ÑÑÐ¼Ñ Ð¸ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð¾ Ð±Ð°ÐºÐ¾Ð² Ð½Ð°ÐºÐ¾Ð¿Ð¸ÑÐµÐ»ÐµÐ¹, Ð²ÑÐµÐ¼Ñ Ð²ÑÐ´ÐµÑÐ¶ÐºÐ¸ ÐÐ Ð Ð´Ð»Ñ ÑÐ¿ÐµÑÐºÐ°Ð½Ð°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸.ÐÐ¿ÑÐµÐ´ÐµÐ»Ð¸ÑÑ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð¾ Ð¶Ð¸ÑÐµÐ»ÐµÐ¹, ÐºÐ¾ÑÐ¾ÑÐ¾Ðµ Ð¼Ð¾Ð¶ÐµÑ Ð¾Ð±ÐµÑÐ¿ÐµÑÐ¸ÑÑ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼ÑÐ¹ Ð¾Ð±ÑÑÐ¼ ÑÑÐ¾ÑÐ½ÑÑ Ð²Ð¾Ð´ Ð´Ð»Ñ ÑÐ°Ð·Ð±Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ð¶Ð¸Ð´ÐºÐ¸Ñ Ð¾ÑÑÐ¾Ð´Ð¾Ð² Ð´Ð¾ Ð¿ÑÐµÐ´ÐµÐ»ÑÐ½Ð¾ Ð´Ð¾Ð¿ÑÑÑÐ¸Ð¼ÑÑ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ð¹Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð¸ Ð¿Ð¾ÑÑÑÐ¾ÐµÐ½Ñ Ð¸ Ð¿ÑÐ¾Ð°Ð½Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½Ñ ÑÑÐ½ÐºÑÐ¸Ð¸ Ð²ÑÐ²ÐµÐ´ÐµÐ½Ð¸Ñ Ð Ð¤Ð, Ð²ÑÑÐ¸ÑÐ»ÐµÐ½ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼ÑÐ¹ Ð¾Ð±ÑÑÐ¼ ÐºÐ°Ð½Ð°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸ Ð´Ð»Ñ ÐµÑÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾Ð³Ð¾ ÑÐ°Ð·Ð±Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ð² Ð¸ Ð²Ð½Ðµ ÐÐ Ð¸ ÑÐ¿ÐµÑÐºÐ°Ð½Ð°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸.
description: Topic of the final qualification work: "Management of liquid radioactive waste after radionuclide therapy Sr-89, I-123".This work is devoted to the consideration of different options for handling liquid radioactive waste (LRW) generated in nuclear medicine secretions when using the following radiopharmaceuticals (RP) - 123I-MIBG, 89Sr-dichloride. The aim of the work was to assess the activity of radionuclides in waste generated by the use of 123I-MIBG in radionuclide diagnostics (RND) and 89Sr-dichloride in radionuclide therapy (RNT) and safe methods of handling these LRW. To achieve this goal, the following tasks were set:1. To study the literature related to recommendations on the use of radiopharmaceutical data, their excretion from the body;2. Assess the activity of radionuclides in waste;3. Determine the volume of sewage in a medical organization (MO) sufficient to dilute liquid waste to the maximum allowable value.4. Calculate the volume and number of storage tanks, the holding time of LRW for special sewage.5. Determine the number of inhabitants that can provide the necessary volume of wastewater to dilute liquid waste to the maximum allowable valuesIn the course of the work, the functions of removing radiopharmaceuticals were built and analyzed, the required volume of sewage for natural dilution in and outside the Moscow Region and special sewerage was calculated.